Rossmore Private Capital Buys 155 Shares of Novo Nordisk A/S (NYSE:NVO)

Rossmore Private Capital grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 0.7% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 23,155 shares of the company’s stock after acquiring an additional 155 shares during the period. Rossmore Private Capital’s holdings in Novo Nordisk A/S were worth $2,757,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. MQS Management LLC bought a new stake in Novo Nordisk A/S during the third quarter valued at $363,000. Moser Wealth Advisors LLC boosted its position in shares of Novo Nordisk A/S by 8.5% during the 3rd quarter. Moser Wealth Advisors LLC now owns 13,258 shares of the company’s stock valued at $1,579,000 after acquiring an additional 1,035 shares during the last quarter. Dillon & Associates Inc. increased its position in shares of Novo Nordisk A/S by 0.5% in the third quarter. Dillon & Associates Inc. now owns 283,417 shares of the company’s stock worth $33,727,000 after purchasing an additional 1,271 shares during the last quarter. RPG Investment Advisory LLC bought a new stake in Novo Nordisk A/S during the third quarter valued at approximately $6,952,000. Finally, Aptus Capital Advisors LLC grew its stake in Novo Nordisk A/S by 33.2% in the 3rd quarter. Aptus Capital Advisors LLC now owns 3,774 shares of the company’s stock worth $449,000 after buying an additional 940 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on NVO shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $107.05 on Wednesday. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15. The stock has a market capitalization of $480.39 billion, a P/E ratio of 34.64, a P/E/G ratio of 1.32 and a beta of 0.42. The company’s 50-day moving average is $120.23 and its 200 day moving average is $130.08. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.